Ascendis Pharma A/S
NASDAQ:ASND
Ascendis Pharma A/S
NASDAQ:ASND
Price:
227.5
USD
-5.41%
Market Closed
Market Cap:
$13.8B
Relative Value
The Relative Value of one
ASND
stock under the Base Case scenario is
198.51
USD.
Compared to the current market price of 227.5 USD,
Ascendis Pharma A/S
is
Overvalued by 13%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
ASND
Relative Value
Base Case
198.51
USD
Overvaluation 13%
Multiples Across Competitors
ASND Competitors Multiples
Ascendis Pharma A/S Competitors
Ascendis Pharma A/S Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| DK |
|
Ascendis Pharma A/S
NASDAQ:ASND
|
14.1B USD | 16.5 | -52.1 | -96.4 | -83.9 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
402.5B USD | 6.6 | 96.2 | 15.8 | 21.9 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
203.5B USD | 5.5 | 26.4 | 15.1 | 15.1 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
181.2B USD | 6.2 | 21.3 | 13.3 | 16.4 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
125.1B USD | 10.4 | 31.6 | 23.9 | 25 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
81.9B USD | 5.7 | 18.2 | 13.6 | 15.5 | |
| AU |
|
CSL Ltd
ASX:CSL
|
68.2B AUD | 3.1 | 34.6 | 11.4 | 14.4 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 | |
| NL |
|
argenx SE
XBRU:ARGX
|
38.5B EUR | 10.9 | 35.2 | 38.2 | 39 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
